Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, United States.
Bioorg Med Chem Lett. 2010 Mar 1;20(5):1559-64. doi: 10.1016/j.bmcl.2010.01.067. Epub 2010 Jan 21.
Through a combination of screening and structure-based rational design, we have discovered a series of N(1)-(5-(heterocyclyl)-thiazol-2-yl)-3-(4-trifluoromethylphenyl)-1,2-propanediamines that were developed into potent ATP competitive inhibitors of AKT. Studies of linker strand-binding adenine isosteres identified SAR trends in potency and selectivity that were consistent with binding interactions observed in structures of the inhibitors bound to AKT1 and to the counter-screening target PKA. One compound was shown to have acceptable pharmacokinetic properties and to be a potent inhibitor of AKT signaling and of in vivo xenograft tumor growth in a preclinical model of glioblastoma.
通过筛选和基于结构的合理设计相结合，我们发现了一系列 N(1)-(5-(杂环基)-2-噻唑基)-3-(4-三氟甲基苯基)-1,2-丙二胺，它们被开发成 AKT 的有效 ATP 竞争抑制剂。对连接子链结合腺嘌呤类似物的研究确定了效力和选择性的 SAR 趋势，这些趋势与抑制剂与 AKT1 结合以及与对照筛选靶标 PKA 结合的结构中观察到的结合相互作用一致。一种化合物表现出可接受的药代动力学特性，并且是 AKT 信号的有效抑制剂，并在胶质母细胞瘤的临床前模型中抑制体内异种移植肿瘤的生长。
